Financial Results for the Fiscal Year Ended September 2025 (Japanese GAAP) (Non-Consolidated)

PRISM BioLab is pleased to announce that we have achieved the initial milestone in our drug discovery collaboration with Ono Pharmaceutical Co., Ltd. and will receive an upfront payment. For more details, please click here.

PRISM BioLab is pleased to announce that a Phase I clinical study on drug-drug interactions of PRI-724/OP-724 (generic name: foscelbinib), which has been licensed to Ohara Pharmaceutical Co., Ltd., has been initiated. For more details, please click here (Japanese language PDF).

TOKYO, Japan, October 17, 2025: — PRISM BioLab announces that Eisai Co., Ltd. will present clinical trial results and biomarker exploration data for E7386, co-created by PRISM BioLab and Eisai, in combination with lenvatinib mesylate, at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 22, 2025....

PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on September 30, 2025. For more details, please click here (Japanese language PDF).

We would like to announce that PRISM BioLab and Servier have mutually agreed to terminate the collaboration and licensing agreement previously established between the two companies. For more details, please click here (English language PDF).

We would like to announce that PRISM BioLab and Eli Lilly and Company have mutually agreed to terminate the collaboration and licensing agreement previously established between the two companies. For more details, please see the full announcement below: https://contents.xj-storage.jp/xcontents/AS09340/e4067309/8794/4b19/8225/2fb73b3fca54/140120250728521212.pdf

PRISM BioLab is pleased to announce that we obtained a patent for our novel compound library on May 30th, 2025. For more details, please click here (Japanese language PDF).

TOKYO, Japan, 23 May 2025: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386, created through collaboration research with Eisai Co., Ltd. , and Lenvatinib mesylate (“lenvatinib”) will be presented by...

CEO Dai Takehara will participate in the “103rd IR Seminar for Individual Investors” hosted by Logmi Finance on Saturday, May 17, 2025. As a company committed to sustainable growth and corporate value enhancement, we actively promote dialogue with shareholders and investors through our proactive IR activities. We will continue our efforts to communicate information and...